Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Recommendation of “Buy” from Analysts

Denali Therapeutics Inc. (NASDAQ:DNLI) has earned a consensus rating of “Buy” from the sixteen ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, twelve have given a buy rating and three have assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $32.5833.

DNLI has been the topic of a number of recent research reports. BTIG Research reiterated a “buy” rating and issued a $32.00 target price on shares of Denali Therapeutics in a research note on Friday, December 5th. JPMorgan Chase & Co. increased their price objective on shares of Denali Therapeutics from $24.00 to $26.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Denali Therapeutics in a research note on Monday, September 8th. Wedbush decreased their target price on shares of Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a research report on Thursday, December 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Wednesday, October 8th.

Denali Therapeutics Stock Down 1.0%

NASDAQ:DNLI opened at $16.41 on Friday. The company has a current ratio of 9.79, a quick ratio of 9.79 and a debt-to-equity ratio of 0.01. The stock has a 50 day moving average of $17.28 and a 200-day moving average of $15.54. The firm has a market capitalization of $2.41 billion, a PE ratio of -5.64 and a beta of 1.11. Denali Therapeutics has a 52 week low of $10.57 and a 52 week high of $24.34.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.02. The business’s revenue for the quarter was up .0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.63) earnings per share. Analysts predict that Denali Therapeutics will post -2.71 EPS for the current year.

Institutional Trading of Denali Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Invesco Ltd. boosted its position in Denali Therapeutics by 55.9% during the 1st quarter. Invesco Ltd. now owns 189,427 shares of the company’s stock worth $2,575,000 after acquiring an additional 67,949 shares during the period. Hsbc Holdings PLC lifted its holdings in Denali Therapeutics by 73.7% in the first quarter. Hsbc Holdings PLC now owns 58,003 shares of the company’s stock worth $779,000 after purchasing an additional 24,613 shares during the period. AlphaQuest LLC grew its position in Denali Therapeutics by 260.0% in the 1st quarter. AlphaQuest LLC now owns 25,060 shares of the company’s stock valued at $341,000 after buying an additional 18,099 shares in the last quarter. Walleye Capital LLC grew its position in Denali Therapeutics by 77.8% in the 1st quarter. Walleye Capital LLC now owns 44,138 shares of the company’s stock valued at $600,000 after buying an additional 19,318 shares in the last quarter. Finally, Trexquant Investment LP increased its stake in Denali Therapeutics by 86.7% during the 1st quarter. Trexquant Investment LP now owns 113,224 shares of the company’s stock valued at $1,539,000 after buying an additional 52,568 shares during the period. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.